acquired
Stage
1
Investors
About
Amniotics develops stem cell-based therapeutics using mesenchymal stem cells derived from full-term amniotic fluid for treating severe life-threatening diseases, with a focus on regenerative medicine applications.
Explore Amniotics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.